A Dominant Role for the Immunoproteasome in CD8\(^+\) T Cell Responses to Murine Cytomegalovirus

Sarah Hutchinson\(^1\), Stuart Sims\(^1\), Geraldine O’Hara\(^1\), Jon Silk\(^2\), Uzi Gileadi\(^2\), Vincenzo Cerundolo\(^2\), Paul Klenerman\(^1\)*

\(^1\) Nuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom, \(^2\) Weatherall Institute of Molecular Medicine, Molecular Immunology Group, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Abstract

Murine cytomegalovirus (MCMV) is an important animal model of human cytomegalovirus (HCMV), a β-Herpesvirus that infects the majority of the world’s population and causes disease in neonates and immunocompromised adults. CD8\(^+\) T cells are a major part of the immune response to MCMV and HCMV. Processing of peptides for presentation to CD8\(^+\) T cells may be critically dependent on the immunoproteasome, expression of which is affected by MCMV. However, the overall importance of the immunoproteasome in the generation of immunodominant peptides from MCMV is not known. We therefore examined the role of the immunoproteasome in stimulation of CD8\(^+\) T cell responses to MCMV – both conventional memory responses and those undergoing long-term expansion or “inflation”. We infected LMP7\(^+\) and C57BL/6 mice with MCMV or with newly-generated recombinant vaccinia viruses (rVV) encoding the immunodominant MCMV protein M45 in either full-length or epitope-only minigene form. We analysed CD8\(^+\) T cell responses using intracellular cytokine stain (ICS) and MHC Class I tetramer staining for a panel of MCMV-derived epitopes. We showed a critical role for immunoproteasome in MCMV affecting all epitopes studied. Interestingly we found that memory “inflating” epitopes demonstrate reduced immunoproteasome dependence compared to non-inflating epitopes, M45-specific responses induced by rVV remained immunoproteasome-dependent. These results help to define a critical restriction point for CD8\(^+\) T cell epitopes in natural cytomegalovirus (CMV) infection and potentially in vaccine strategies against this and other viruses.

Introduction

Human cytomegalovirus (HCMV) is a β-Herpesvirus, a double-stranded DNA virus encoding 160 proteins, which infects most of the world’s population [1]. Infection is asymptomatic in immunocompetent hosts; however, virus is not cleared after acute infection and persists lifelong. In immunocompromised hosts, such as those infected with HIV and bone marrow transplant (BMT) recipients, HCMV infection may cause severe disease. Murine cytomegalovirus (MCMV) is a well-characterized animal model for HCMV, reflecting many key aspects of the immunology of human infection [2].

CD8\(^+\) T cells are important mediators of immune responses to HCMV and MCMV [3,4,5,6,7]. CD8\(^+\) T cells in combination with other antiviral mediators limit CMV reactivation in immunocompetent hosts and protect against disease in immunosuppressed hosts. Adoptive transfer of anti-CMV CD8\(^+\) T cells protects from CMV-induced disease in mouse and man [8,9]. During the chronic phase of CMV infection CD8\(^+\) T cell responses to certain epitopes increase in number over time; this phenomenon, known as ‘memory inflation’, is characteristic of CMVs [10,11,12,13,14]. The “superboosting” nature of the immune response can be exploited in CMV-based vaccines to induce long-term protective antiviral CD8\(^+\) T cell responses [14,15]. However the mechanism of memory inflation and the criteria that distinguish those responses that inflate compared to those that enter into a classical memory pool are not known.

The CD8\(^+\) T cell response to virus infection is driven by the presentation of peptide by professional antigen presenting cells (APCs) and infected targets. Generation of the peptide repertoire requires a series of components responsible for cleavage and presentation [16]. The immunoproteasome is one such component, an inducible form of the proteasome thought to be optimised for production of MHC class I ligands [17]. All cells contain constitutive proteasomes and respond to interferon-gamma (IFN-γ) by upregulation of immunoproteasome expression. Immune cells, including professional APCs such as dendritic cells (DCs) and macrophages, also constitutively express immunoproteasomes [18,19,20].

The role of the immunoproteasome in vivo is not yet defined. Constitutive and immuno-proteasomes produce a different profile of potential CD8\(^+\) T cell epitopes and epitope precursors from a given polypeptide. In general, immunoproteasome digests contain more potential MHC class I ligands than the constitutive
counterparts [21]. However, most known microbial CD8+ T cell epitopes are produced by both types of proteasome in cell-free assays and by infected APCs [22]. Mice lacking functional genes for one or two of the three catalytic subunits of the immunoproteasome (LMP7, LMP2 and MECL-1) produce many expected CD8+ T cell responses to infection, although the overall impact is not yet clear [19,23,24,25,26]. One study of lymphocytic choriomeningitis virus (LCMV) infection in LMP7-/- mice, showed no difference in CD8+ T cell responses or difference in viral load and disease [27]. However, this study showed that in DNA vaccination with LCMV glycoprotein there is enhanced presentation of one epitope (GP276) in the absence of LMP7, a feature noted before in LMP7-/- mice when a RVV expressing the LCMV glycoprotein was used [19]. Recently, it has been shown that LMP7 inhibition using a small molecule inhibitor of LMP7 strongly downregulated the CTL response to LCMV- GP33 and NP396 (but not sub-dominant epitopes) during LCMV infection [28]. Thus, while it is known that specific epitopes can show immunoproteasome dependence, the overall dependence of antiviral T cell responses on immunoproteasomes is not fully defined.

MCMV and HCMV encode numerous immunoasins which affect components of the MHC class I antigen processing pathway [29]. IFN-γ-mediated upregulation of immunoproteasome expression is normally an important host response to viral infection. However, in HCMV- or MCMV-infected cells it has been shown that upregulation of the immunoproteasome does not occur in response to IFN-γ [30]. In murine cells this effect is mediated by the MCMV protein M27, which prevents signaling through the IFN-γ receptor (IFNGR) by binding to the cellular signalling intermediate STAT2 (previously thought to transduce only signals through the interferon-α receptor (IFNAR)) [31]. It was proposed that if the repertoire of antiviral CD8+ T cells was selected on constitutively immunoproteasome-rich professional APCs, such as DCs and macrophages, they might predominantly be specific for epitopes that are better presented by the immunoproteasome [30]. If this were true, M27-mediated suppression of immunoproteasome expression in infected tissue cells might protect infected cells from detection by antiviral CD8+ T cells.

We therefore investigated the role of the immunoproteasome in induction of CD8+ T cell responses to MCMV. LMP7-/- mice were infected with MCMV or novel recombinant vaccinia viruses (rVVs) expressing MCMV proteins. Antigen-specific CD8+ T cell responses to a panel of previously defined peptide epitopes were quantified by ex vivo MHC class I tetramer analysis and IFN-γ intracellular cytokine stains (ICS). A key role for the immunoproteasome was revealed in modulating the immunodominant response in acute disease and in a range of other epitopes. This study reveals a major role for the immunoproteasome in determining the CD8+ T cell repertoire in MCMV, both in acute infection (7 days) and chronic infection (>50 days).

Results

Responses to M45 are not detected in LMP7-/- mice

In wild type mice, the most dominant CD8+ T cell response to MCMV after acute infection (day 7) recognizes the Dα-restricted epitope M45 HGIRNASA1 (hereafter described as “M45”) [32,33]. We aimed to determine the role of the immunoproteasome in induction of this response by comparing M45-specific responses to MCMV infection in C57BL/6 mice with those in gene-targeted knockout mice lacking a functional gene for the immunoproteasome subunit LMP7 (LMP7-/-) backcrossed onto a C57BL/6 background [26]. LMP7-/- and C57BL/6 mice were injected intravenously with MCMV. Seven days later, peripheral blood or splenocytes were prepared and M45-specific responses evaluated by tetramer stain or IFN-γ ICS (Figure 1). Seven days post-infection (p.i.) is the peak of the cellular immune responses to MCMV and conventionally referred to as acute infection.

As expected, 4% of CD8+ T cells from the peripheral blood stained positive with the M45 tetramer in C57BL/6 mice acutely infected with MCMV (Figure 1A). In contrast, no M45-specific CD8+ T cells were detected in the peripheral blood of LMP7-/- mice. To determine whether M45-specific cells were present at another site, splenocytes from LMP7-/- and C57BL/6 acutely infected mice were stained with M45 tetramer. M45-specific splenocytes were below the limit of detection in infected LMP7-/- mice (Figure 1B), compared to substantial responses (5%) detected in C57BL/6 mice. The function of M45-specific CD8+ T cells in the spleens of acutely infected LMP7-/- mice was assessed by ex vivo IFN-γ ICS. No CD8+ T cells from the spleens of infected LMP7-/- mice produced IFN-γ in response to peptide in ex vivo IFN-γ ICS (Figure 1C) compared with 1.5% of CD8+ T cells in MCMV-infected C57BL/6 mice.

It was possible that the pattern of responses to M45 would be affected by the immunoproteasome in a temporal fashion (i.e. responses may be delayed rather than absent). Using MHC class I tetramer staining to detect M45-specific responses in the blood of LMP7-/- mice up to 100 days p.i., it is apparent that the response to M45 remained below the limit of detection at all time points tested (Figure 1D). In comparison, in C57BL/6 mice, M45-specific cells were maintained over time at a low level (0.4% of CD8+ T cells; Figure 1D).

CD8 responses to m141 are not detected in LMP7-/- mice

During acute MCMV infection, a second protein which contains a highly targeted epitope in C57BL/6 mice is m141 [32]. Compared with 1.2% of CD8+ T cells in acutely infected C57BL/6 mice (Figure 2A), no m141-specific CD8+ T cells were detected in the blood of LMP7-/- mice at 7 days p.i. IFN-γ was not produced in response to m141 peptide by splenocytes from infected LMP7-/- mice, whereas 0.5% of CD8+ T cells from C57BL/6 mice mounted an IFN-γ response to m141 peptide (Figure 2B). In C57BL/6 mice, the number of m141-specific T cells did not inflate over time [11]. The m141 specific responses in the blood of LMP7-/- mice were examined using tetramers between days 7 and 100 p.i. At no point in time were m141-specific CD8+ T cells detected in the peripheral blood of LMP7-/- mice (Figure 2C).

Responses to M38a and m139 are affected by LMP7 deletion

The M38 and m139 proteins of MCMV are major targets of the CD8+ T cell response in C57BL/6 mice. In contrast to M45 and m141 described above, CD8+ T cell responses to M38a and m139 both undergo memory inflation. The acute CD8+ T cell response to M38a is relatively small and expands only later compared to CD8+ T cells specific for m139, which are also relatively abundant during the acute phase of infection [11]. Peripheral blood of MCMV-infected LMP7-/- and C57BL/6 mice was assayed for m139-specific CD8+ T cells over a 100-day time course (Figure 3A). The CD8+ T cell response to m139 in acute infection was reduced (0.3%) relative to the wild type response (1.5%), but remained detectable. The difference was greater in chronic infection; the m139-specific response in C57BL/6 mice increased to 3.5% by 100 days p.i., whereas the
m139-specific response of LMP7<sup>−/−</sup> mice remained static over time (Figure 3A). The same pattern was evident in spleens. IFN-γ-secreting m139-specific CD8<sup>+</sup> T cells were also detected in the spleens of LMP7<sup>−/−</sup> mice 100 days p.i. compared to a small but readily detectable response (0.4%) in C57BL/6 mice (Figure 4A). By 100 days p.i., M38a-specific responses were easily detectable in both C57BL/6 and LMP7<sup>−/−</sup> mice (2%) compared to C57BL/6 mice (5%). The increase in frequency of M38a-specific CD8<sup>+</sup> T cells over time in C57BL/6 and LMP7<sup>−/−</sup> mice indicated that memory inflation had occurred in both strains.

Figure 1. CD8<sup>+</sup> T cell responses to M45 in LMP7<sup>−/−</sup> mice infected with MCMV. A. LMP7<sup>−/−</sup> mice and C57BL/6 control mice were injected intravenously (i.v.) with 1 x 10<sup>6</sup> plaque forming units (pfu) MCMV or an equivalent volume of phosphate buffered saline (PBS). Seven days p.i. peripheral blood was sampled by tail bleed. Whole blood was stained with fluorochrome-conjugated soluble tetrameric complexes (M45 H-2<sup>D<sub>b</sub></sup> HGIRNASFI<sup>985-993</sup>) and anti-CD8 antibody, and red blood cells lysed, before analysis by FACS. B. Lymphocytes were prepared from peripheral blood and spleen of LMP7<sup>−/−</sup> and C57BL/6 control mice 7 days p.i. (n = 5) or PBS treated (blood: n = 2; spleen: n = 4) and subjected to tetramer stain and FACS analysis as above. The plots show the frequency of M45<sup>D<sub>b</sub></sup>-specific cells among CD8<sup>+</sup> T cells. SEM was less than 0.1%. C. Splenocytes were prepared from spleens of LMP7<sup>−/−</sup> and C57BL/6 control mice (n = 5) 7 days p.i. and incubated in either media containing synthetic peptide HGIRNASFI or media alone, in the presence of Brefeldin A (BFA). After 5 hours cells were stained for CD8 and intracellular IFN-γ and analysed by FACS. The plots show % CD8<sup>+</sup> T cells producing IFN-γ in response to peptide or media alone. SEM was less than 0.1%. D. Peripheral blood was sampled from LMP7<sup>−/−</sup> and C57BL/6 control mice (n = 3) at 7, 40, 60 and 100 days p.i. and subjected to tetramer stains using M45<sup>D<sub>b</sub></sup> HGIRNASFI tetramer and FACS analysis as for Figure 1A. The plot shows the frequency of M45<sup>D<sub>b</sub></sup>- specific cells among CD8<sup>+</sup> T cells over a 100 day time course.

doi:10.1371/journal.pone.0014646.g001
Subdominant responses occur in LMP7−/− mice but at reduced frequencies

Over 20 MCMV-derived CD8 epitopes have been defined in C57BL/6 mice [32]. It was possible that a previously subdominant epitope would be increased in LMP7−/− mice, due to altered antigen processing or altered competition from other responses. As described above four immunodominant responses occurred at lower frequencies in LMP7−/− mice relative to C57BL/6 mice (M45, m139, and M38a and m141). To analyze the other responses, splenocytes from LMP7−/− and C57BL/6 mice, from day 7 and >50 p.i., were exposed to a panel of synthetic peptides corresponding to MCMV-derived CD8+ T cell epitopes previously defined in C57BL/6 mice (Table S1). Peptide-specific IFN-γ production by splenocytes from infected mice was assessed using ICS. In acute infection 10 out of 11 epitopes tested that stimulated responses in C57BL/6 mice also stimulated responses in splenocytes from acutely infected LMP7−/− mice (Figure 5A).

The frequency of 9 out of 11 responses was reduced relative to the equivalent responses in wild type mice (Figure 5A). Of the subdominant responses, two responses, to epitopes from M76 and M33, occurred at the same frequency in LMP7−/− mice as in C57BL/6 mice, but overall these did not become immunodominant. The magnitude of all sub-dominant responses was low, close to the value of background for the assay.

At later timepoints 5 out of 5 epitopes that stimulated responses in C57BL/6 mice >50 days p.i. also stimulated responses in splenocytes from chronically infected LMP7−/− mice (Figure 5B and C). All responses were reduced in frequency in LMP7−/− mice relative to wild type responses.

The M45 response is reduced in LMP7−/− mice even when M45 is expressed by rVVs

To determine whether loss of the CD8+ T cell response to M45 in LMP7−/− was a quality associated with herpesvirus infection rather than a quality of the protein required expression of M45 protein in a different viral context to that in the native herpesvirus. Therefore, a novel rVV [34] expressing the M45 CD8+ T cell epitope as part of the full-length M45 protein (referred to as M45-VV), was constructed (Figure 6A). This was used to infect LMP7−/− mice and assay for CD8+ T cell responses to M45.

C57BL/6 and LMP7−/− mice were injected intravenously with M45-VV and 7 days p.i. peripheral blood was sampled. In C57BL/6 mice, 1% of CD8+ T cells were tetramer-positive (Figure 6B), while in contrast, peripheral blood from LMP7−/− mice contained no M45-specific CD8+ T cells as determined by tetramer stains (Figure 6B). Thus the effect of LMP7 functional gene deletion on response to M45 was similar in LMP7−/− mice infected with MCMV or with M45-VV.

We next sought to differentiate whether either [1] loss of immunoprotosomal function or [2] a hole in the T cell repertoire might explain why the CD8+ T cells of LMP7−/− mice failed to respond to M45 expressed from MCMV (Fig. 1) or M45-VV (Fig. 6B) [35–36]. To address this question, a second rVV was constructed that expressed the immunodominant 985–993 epitope of M45 from a minigene (M45 epitope-VV; Figure 6A and Table S2), C57BL/6 mice and LMP7−/− mice were intravenously inoculated with M45 epitope-VV to determine if a CD8+ T cell response was mounted. On day 7 p.i. 4% of peripheral blood CD8+ T cells in both C57BL/6 mice and LMP7−/− mice that received the M45 epitope-VV were specific for the M45 tetramer. We conclude that absence of M45-specific naïve T-cells (i.e. a hole in the repertoire) does not explain the failure of LMP7−/− mice to respond to the M45 protein when expressed from MCMV or a
vaccinia vector. Rather, the results imply that loss of the LMP7 protein compromises immunoproteasome function, which appears to be critical if the M45 is to be proteolytically processed such that the M45 immunodominant epitope is presented to CD8+ T cells.

Discussion

In this study, we addressed the hypothesis that during MCMV infection CD8+ T cell responses specific for certain epitopes are better processed by the immunoproteasome than the constitutive proteasome. Immunoproteasomes and constitutive proteasomes produce differing sets of potentially antigenic peptides during MHC class I antigen processing for presentation to CD8+ T cells [21]. Professional APCs involved in priming naive CD8+ T cells constitutively express immunoproteasomes [18,20]. In contrast, non-immune cells require exposure to IFN-γ to upregulate immunoproteasome expression [37]. During MCMV infection the viral protein M27 prevents IFN-γ-mediated upregulation of immunoproteasome expression in infected cells by blocking signaling through the IFNGR [30,31]. It was possible that M27-mediated resistance to upregulation of immunoproteasome expression would protect infected cells from lysis by CD8+ T cells primed with constitutively immunoproteasome-rich cells [30]. This, however, is dependent on whether CD8+ T cell responses to MCMV are specific for epitopes better processed by the immunoproteasome than the constitutive proteasome (“immunoproteasome dependent”).

Using MCMV infection of LMP7-/- mice and ex vivo CD8+ T cell assays for number and function, we found that the M45-specific CD8+ T cell response to MCMV that is immunodominant in C57BL/6 mice is profoundly affected by loss of wild-type immunoproteasome in LMP7-/- mice. Since all MCMV-derived CD8+ T cell epitopes tested were affected by the loss of wild-type immunoproteasome in LMP7-/- mice, and in studies of other viruses the effects on different epitopes from the same virus have been divergent [22], we speculated that the unusually consistent effect of the immunoproteasome was associated with herpesviral infection, and not specific qualities of the primary sequences of the proteins from which the epitopes were derived. Expressing the MCMV M45 (a protein
containing the dominant CD8\(^+\) T cell epitope in C57BL/6 mice) in the context of rVV allowed testing of this. However, no response to M45 detectable directly ex vivo was induced in LMP7\(^{-/-}\) mice infected with rVV expressing full-length M45. The virus induced M45-specific responses in C57BL/6 mice, and LMP7\(^{-/-}\) mice produced M45-specific CD8\(^+\) T cell responses to rVV expressing only the M45 minimal epitope from a minigenome. Therefore at least in the case of CD8\(^+\) T cell response to M45 the requirement for wild type immunoproteasome was maintained in the absence of MCMV infection. This suggested that M45 primary sequence and not viral interference determined the effect of the immunoproteasome on stimulation of M45-specific CD8\(^+\) T cell responses during MCMV infection. By extension, this suggests that MCMV-derived CD8\(^+\) T cell epitopes with responses reduced in LMP7\(^{-/-}\) mice might have protein primary sequences that could be better processed by immunoproteasomes. Further work would be required to test this hypothesis more extensively; however, if true, these would be useful data points for immunoproteasome cleavage prediction. It should be pointed out that LMP7 deficient mice also lack a contribution from LMP2 and MECL in immunoproteasomes [38], so it remains open which of these subunits is actually required for the generation of the different epitopes.

These findings have a number of implications for viral pathogenesis. Firstly it is known that M45-specific CD8\(^+\) T cell populations have limited protective capacity in a bone marrow transplant model [33,39]. This can be potentially explained by the fact while these responses may be readily generated in LMP7\(^{-/-}\) control mice 7 days p.i. (n = 5), pooled, and exposed to each of nineteen synthetic peptides corresponding to defined CD8 epitopes of MCMV (Table S1), or media alone, in the presence of BFA for 5 hours. Splenocytes were subjected to CD8 surface stain, IFN-\(\gamma\) ICCS and FACS analysis as for Figure 1C. Frequency of IFN-\(\gamma\) cells among CD8\(^+\) T cells in infected C57BL/6 or LMP7\(^{-/-}\) mice, 7 days p.i. is shown for each peptide. Data is shown with background subtracted for both mouse strains, only for responses that in C57BL/6 mice were above background. Background is defined as three times the sum of the mean and standard error of the mean response to stimulation with media control alone. B. A similar analysis was to that described in Fig 5A was performed for CD8\(^+\) T cell responses detectable at 100 days p.i. C. Example ICCS staining for C57BL/6 and LMP7\(^{-/-}\) mice (day 100) in response to M45, m139 and M38 peptides.

**Figure 5. Breadth of CD8\(^+\) T cell responses to MCMV in LMP7\(^{-/-}\) mice.** A. Splenocytes were prepared from spleens of LMP7\(^{-/-}\) and C57BL/6 control mice 7 days p.i. (n = 5), pooled, and exposed to each of nineteen synthetic peptides corresponding to defined CD8 epitopes of MCMV (Table S1), or media alone, in the presence of BFA for 5 hours. Splenocytes were subjected to CD8 surface stain, IFN-\(\gamma\) ICCS and FACS analysis as for Figure 1C. Frequency of IFN-\(\gamma\) cells among CD8\(^+\) T cells in infected C57BL/6 or LMP7\(^{-/-}\) mice, 7 days p.i. is shown for each peptide. Data is shown with background subtracted for both mouse strains, only for responses that in C57BL/6 mice were above background. Background is defined as three times the sum of the mean and standard error of the mean response to stimulation with media control alone. B. A similar analysis was to that described in Fig 5A was performed for CD8\(^+\) T cell responses detectable at 100 days p.i. C. Example ICCS staining for C57BL/6 and LMP7\(^{-/-}\) mice (day 100) in response to M45, m139 and M38 peptides.

doi:10.1371/journal.pone.0014646.g005

Notably responses to M38 and m139 are sustained or increase over time compared to classical “memory” responses, a phenomenon described as memory “inflation”. This feature was first described in the BALB/c (susceptible) model [13,14], but subsequently observed in the C57BL/6 (resistant) model [11] using natural and transgenic epitopes. Re-exposure of such “inflating” populations to antigen over time appears to underlie generation of these CD8\(^+\) T cell pools [2], a hypothesis supported by the “effector memory” phenotypic characteristics detectable in the cell subsets [11,12]. One reason proposed why specific epitopes attract “inflating” populations compared to others, is the generation of peptides that escape the viral mechanisms for downregulation of antigen processing. In particular, IE-1 derived peptides might generate inflating populations since they are generated early after infection [14]. However, this is not uniquely the case as epitopes from later expressed proteins can also be associated with inflation [13,32] and there are situations where distinct peptides may be generated from the same protein (M38) in which one epitope is inflating while the other is not [11]. We note that the two inflating epitopes included in this study (M38 and m139) had the least dependence on immunoproteasomes. We speculate that this feature could contribute to their unique immunologic profile. During chronic infection, in addition to the constraints placed upon antigen presentation by viral gene expression kinetics and immunoevasins, the ability to be presented by cells low in LMP7 may provide an additional “filter” to limit the number of inflating epitopes.

While the M38 CD8\(^+\) T cell response does show inflation over time, the m139 response, whilst still dominant, is maintained stably and does not substantially further increase over time. This feature has been noted previously in some MCMV responses [11]; some responses are clearly maintained by antigen exposure (and thus do not revert to “central” memory), but show long-term stability rather than increase. In this case the overall size of the population may be somewhat reduced compared to wild-type response due to a limitation in antigen presentation, or alternatively by competition with newly arising responses.

The question of whether other novel CD8\(^+\) T cell responses arise is an important one. As a marker of overall T cell memory, there was not a deficit in the proportion of splenic CD8\(^+\) T cells responding to PMA/Inomycin through IFN-\(\gamma\) secretion in LMP7 deficient mice at day 100 (data not shown). Thus it is possible that responses outside those measured are entering the memory pool. Further detailed analyses of novel specificities is required to define any new responses, which may potentially normally be limited by immunoproteasomes [19].

The responses analyzed in this paper remain functional, as measured here by IFN-\(\gamma\) secretion, although not all cells demonstrated using tetramer staining were detectable in short term functional assays (e.g. Fig 1). Overall, when this has been extensively analyzed [11,12,14] these responses are both function-
al (in terms of cytokine secretion, killing and proliferation) and protective, and in contrast to LCMV there is no evidence of exhaustion. Given recent studies of the impact of LMP7 inhibition on T cell derived IL-17 in tissue, it would be interesting to explore this specific aspect in future in MCMV [48].

Combining the data we therefore propose a “2-cell” model for the role of the immunoproteasome in MCMV (Figure 7). Under normal circumstances in acute disease, antigen may be presented or cross-presented on DCs and prime strong responses: since DCs constitutively express immunoproteasomes, and the responses are highly immunoproteasome dependent, a wide range of such responses will be generated. Such responses are, however, unable to protect infected cells against infection if these cells downregulate LMP7. As infection is controlled, antigen production is limited by a variety of factors, including NK cells, but in LMP7lo cells, LMP7 dependent epitopes will not be re-presented and classical memory

Figure 6. CD8+ T cell responses to M45 in LMP7−/− mice infected with M45-expressing rVV. A. Recombinant vaccinia viruses (rVVs) were constructed containing foreign genes derived from the genomic sequence of MCMV Smith Strain (ATCC VR-194). Foreign genes were full length gene encoding the MCMV protein M45 (M45-VV), or a ‘minigene’, encoding the antigenic fragment of M45 corresponding to the CD8 epitope M45 H-2 D3 985HGIRNASF993 (M45 epitope-VV). Genes were designed for insertion between restriction sites for restriction endonucleases Apa I (5′) and Kpn I (3′). The diagram shows recombinant genes and proteins encoded by the two rVVs used in this study: M45 VV encoding full-length M45; and M45 epitope-VV, encoding the minimal D3-restricted CD8 epitope of M45 only. B, C. LMP7−/− or C57BL/6 control mice were injected i.v. with 1 × 10^6 pfu M45-VV (B), 1 × 10^6 pfu M45 epitope-VV (C) or an equivalent volume of PBS. Blood was sampled 7 days p.i. by tail bleed. Peripheral blood lymphocytes were subjected to tetramer stain with M45 Db HGIRNSFI tetramer and FACS analysis as for Figure 1A. The frequency of cells specific for M45 H-2 D3 985HGIRNASF993 among CD8+ T cells in the blood of MVacc and MGVacc - infected and mock-infected C57BL/6 and LMP7−/− mice, 7 days after infection, is shown.

doi:10.1371/journal.pone.0014646.g006
will ensue. Epitopes that show some independence from LMP7 will have the potential to be re-presented and from this limited pool, “inflating” epitopes are selected. Since DCs are constitutive expressors of LMP7, this suggests that the cells responsible for antigen presentation during chronic infection could include other APCs or infected cell populations. More generally, this data suggests that DC-based strategies which prime CD8+ T cell responses in an immunoproteasome-rich environment may run the risk of selecting CD8+ T cell populations which are unable to recognize target cells, in settings where a virus (or even tumor) has modified its immunoproteasome cargo.

Overall our findings suggest that LMP7 and the immunoproteasome play a more significant role in MCMV than previously suspected from studies of other virus infections. This may be relevant to human HCMV infection and potentially infection with other viruses which display comparable dynamics. To what extent this situation has evolved to provide a viral advantage is not clear, but the extent of the impact is very evident, and appears to be a property of the viral sequence itself. These data can be added to the renewed accumulation of interest in the impact of the immunoproteasome in infection and inflammation, following studies on LCMV [28] and toxoplasma [49] (recently reviewed in Ref. [50]). Further experiments to explore the role of the immunoproteasome in herpesviral infections will be of great interest in the future.

Methods

Ethics statement: Mouse experiments were performed according to UK Home Office regulations (project licence number PPL 30/2235) and after review and approval by the local ethical review board at the University of Oxford.

Mice and viruses

C57BL/6 and LMP7−/− mice were bred in a specific pathogen free animal facility unit at the John Radcliffe Hospital, University of Oxford, United Kingdom. MCMV (Strain Smith, ATCC: VR-194) was provided by Professor U.H. Koszinowski, Department of Virology, Max von Pettenkofer Institute, Munich, Germany. Vaccinia virus Western Reserve (VVWR, ATCC: VR-1354) was used. Mice were injected intravenously (i.v.) with 1×10⁶ pfu (100 μl) MCMV or rVV as indicated.

Peptides. Peptide stock solutions (1 mM) (Roswell Park Memorial Institute media 1640 (RPMI; Sigma), di-methyl sulfoxide (DMSO) (10%)) were stored at 280°C before use then at 4°C for up to 2 months. DMSO concentrations in final cell assays were less than 0.01%. Synthetic peptides with amino acid sequences matching CD8+ T cell epitopes from MCMV (Table S1) were custom synthesized to 80–85% purity (Weatherall Institute for Molecular Medicine peptide synthesis facility, John Radcliffe Hospital, University of Oxford).

Staining protocols. R10 (RPMI-1640, foetal calf serum (FCS) (10%), PSG (penicillin (5,000 U/ml) streptomycin (5 mg/ml) and glutamine (5 mM)), β-mercaptoethanol (β-ME) (50 mM)) was used for temporary storage of lymphocytes after removal of red blood cells (RBC) and of splenocytes before and during preparation from whole spleens. FACSWash (PBS, FCS (2%), EDTA (5 mM)) was used to suspend lymphocytes during staining for FACS analysis. FACS Fix (phosphate buffered saline (PBS), Para-formaldehyde (PFA) (1%)) was used to fix lymphocytes after staining and prior to FACS analysis. Biotinylated MHC class I molecules refolded with human β-2 microglobulin (β2M) and peptide were stored in PBS at −80°C before use. Antibodies (Ab) for fluorescence activated cell sorting (FACS) analysis included CD8-PerCP or CD8-APC (Invitrogen). Intracellular stains used IFN-γ FITC after stimulation as previously described. All flow cytometry was performed and analyzed using CellQuest3.3 or Flogo acquisition software and FACScalibur flow cytometer (BD Biosciences).

Generation of rVVs. MCMV M45 gene sequence data was derived from NCBI sequence database, accession: ‘MnHV1_gpM45’, NCBI GeneID: 3293809. Primers for amplification and cloning of MCMV gene M45 were Forward primer: aagggc-
ccacctAGTGATGCCCCACAGGTGC; Reverse primer: taggtccATGAGCAGGATACCATCAGGGAGG). BioX-Act Long Mix (Bioline) was used for PCR. For the minigene, complementary oligo-nucleotides (oligos) were designed such that when annealed they form a single short fragment of dDNA or insert encoding the target amino acid sequence of the MHC class I epitope M805HGRNASF935 (Sense strand: ccacctATGAGCAGGATACCATCAGGGAGG). For cloning, Apa I, Kpn I, Sma I and Xmn I restriction enzymes and T4 ligase were obtained from New England Biolabs (NEB). Bacteria competent for transformation used in cloning were TOP10 (Invitrogen), used for amplification of plasmids less than 12 kilobase pairs (kb) in length or XL-1 Blue (Stratagene) used for plasmids greater than 12 kbp.

All rVVs were prepared using previously described protocols [34] and were confirmed by sequencing. For minigene recombinants two primers were used: (Forward: CAAACCCACCCC- and were confirmed by sequencing. For minigene recombinant M45 full-length gene (GCGCCGCGGCCGCTC-PCR using an ‘inside’ primer specific for a sequence unique to the sequenced full-length M45 gene required 16 additional primers GACTTTTTAT; Reverse: TACGTTGAAATGTCCCATCG).

Characteristics

1. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, et al. (2006) Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43: 1143–1151.
2. Kleneman P, Hill A (2005) T cells and viral persistence: lessons from diverse infections. Nat Immunol 6: 873–879.
3. Podlech J, Holbach J, Wirtz N, Steffens HP, Reddehase MJ (1998) Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol 79(Pt 9): 2099–2104.
4. Moss P, Khan N (2004) CD8+ T-cell immunity to cytomegalovirus. Hum Immunol 65: 456–464.
5. Reddehase MJ, Keil GM, Koszinowski UH (1998) The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol 28: 36–61.
6. Reddehase MJ, Keil GM, Koszinowski UH (1998) The cytolytic T lymphocyte response to the murine cytomegalovirus. I. Distinct maturation stages of cytolytic T lymphocytes constitute the cellular immune response during acute infection of mice with the murine cytomegalovirus. J Immunol 160: 482–489.
7. Polic B, Hengel H, Krmpotic A, Trevigliov J, Pavic I, et al. (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188: 1047–1054.
8. Peggs KS, Verfurth S, Piszcz A, Khan N, Guiver M, et al. (2003) Adaptive cellular therapy for early cytomegalovirus infection after allogeneic stem cell transplantation with virus-specific T-cell lines. Lancet 362: 1375–1377.
9. Pahl-Seilbert MF, Jurell M, Podlech J, Thomas D, Desen P, et al. (2005) Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 79: 5040–5041.
10. Holttappes R, Thomas D, Podlech J, Reddehase MJ (2002) Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J Virol 76: 151–164.
11. Munka MW, Choi KS, Pinto AK, Sierra S, Kleneman P, et al. (2006) Four distinct patterns of memory CD8+ T cell responses to chronic murine cytomegalovirus infection. J Immunol 177: 450–458.
12. Sierra S, Rotherhop R, Kleneman P (2005) Evolution of diverse cytadil CD8+ T cell populations after murine cytomegalovirus infection. Eur J Immunol 35: 1113–1123.
13. Karre U, Sierra S, Wagner M, Oserinus A, Hengel H, et al. (2003) Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol 170: 2022–2029.
14. Karre U, Wagner M, Sierra S, Oserinus A, Hengel H, et al. (2004) Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol 78: 2255–2264.
15. Hunsor SG, Vavalle C, Whisan N, Coyle-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293–299.
16. Rock KL, York IA, Sarie T, Goldberg AL (2002) Protein degradation and the production of MHC class I-presented peptides. Adv Immunol 80: 1–70.
17. Goldberg AL, Cescio P, Sarie T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39: 147–164.
18. Magiocco A, Gilliet M, Sallusto F, Lanavecechia A, Notte F, et al. (1999) Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 29: 4037–4042.
19. Basler M, Youhnovski N, Van Den Broek M, Przybylski M, Groettrup M (2004) Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from cytolytic choriomeningitis virus. J Immunol 173: 3925–3934.
20. Nil A, Firta E, Sobek V, Eichmann K, Niedermann G (2004) Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur J Immunol 34: 2601–2609.
21. Tores RE, Nussbaum AK, Degermann S, Schiele M, Emmrich NP, et al. (2001) Discrete cleavage motifs of constitutive and immunoproteasome proteins revealed by quantitative analysis of cleavage products. J Exp Med 194: 1–12.
22. Van den Eynde BJ, Morel S (2001) Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 13: 147–153.
23. Basler M, Moebius J, Elenschl, Groettrup M, Monaco JJ (2006) An altered T cell repertoire in MELI-I deficient mice. J Immunol 176: 6665–6672.
24. Robek MD, Garcia ML, Boyd BS, Chisari FV (2007) Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J Virol 81: 483–491.
25. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR (2001) Immunoproteasomes shape immunodominance hierarchies of antiviral CD8+ T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 193: 1319–1326.
26. Felhög H, Swat W, Laplace C, Kuhn R, Rajewsky K, et al. (1994) MHC class I expression in mice lacking the proteasome subunit LMP7. Science 265: 1234–1237.
27. Nussbaum AK, Rodriguez-Carreno MP, Benning N, Botten J, Whitton JL (2005) Immunoproteasome-deficient mice mount largely normal CD8+ T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination. J Immunol 175: 1153–1160.
28. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, et al. (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15: 781–787.
29. Reddehase MJ (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2: 831–844.
30. Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H (2004) A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol 78: 1831–1842.
31. Zimmermann A, Trilling M, Wagner M, Wilborn M, Bubic I, et al. (2005) A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med 201: 1543–1553.
32. Munks MW, Gold MC, Zajac AL, Doom CM, Morello CS, et al. (2006) Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus. J Immunol 176: 3760–3766.
33. Gold MC, Munks MW, Wagner M, Koszinowski UH, Hill AB, et al. (2002) The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M3-specific CTL but does not alter the immunodominance of the M3-specific CD8 T cell response in vivo. J Immunol 169: 359–365.
34. Chakrabarti S, Brechling K, Moss B (1985) Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5: 3403–3409.
35. Osterloh P, Linkemann K, Tenzer S, Rammensee HG, Radsak MP, et al. (2006) Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc Natl Acad Sci U S A 103: 5042–5047.
36. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL (1993) A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 365: 264–267.
37. Gaczynska M, Rock KL, Goldberg AL (1993) Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365: 264–267.
38. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, et al. (1998) Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 187: 97–104.
39. Holtappels R, Podlech J, Pahl-Sehert MF, Julich M, Thomas D, et al. (2004) Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med 199: 131–136.
40. Palnowski MJ, Giliani U, Salo M, Gallimore A, Millrain M, et al. (2006) Role of immunoproteasomes in cross-presentation. J Immunol 177: 983–990.
41. Hengel H, Koszinowski UH, Conzelmann KK (2005) Viruses know it all: new insights into IFN networks. Trends Immunol 26: 396–401.
42. Salem ML, Hossain MS (2000) In vivo acute depletion of CD8(+)- T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells. Int J Immunopharmacol 22: 707–718.
43. Lathbury IJ, Allan JE, Shewith GR, Scalzo AA (1996) Effect of host genotype in determining the relative roles of natural killer cells and T cells in mediating protection against murine cytomegalovirus infection. J Gen Virol 77(Pt 10): 2605–2613.
44. Polic B, Jonjic S, Pavic I, Crnkovic I, Zorica I, et al. (1996) Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol 77(Pt 2): 217–225.
45. Bubic I, Wagner M, Krempolc A, Saulig T, Kim S, et al. (2004) Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 78: 7336–7344.
46. Voigt V, Forbes CA, Tonkin JN, Dalgic-Ejepot MA, Smith HR, et al. (2003) Marne cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci U S A 100: 13483–13488.
47. Simou CO, Holtschep R, Tervo HM, Bohm V, Daubner T, et al. (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80: 10436–10436.
48. Basler M, Daire M, Moll G, Groettrup M, Kirk CJ (2010) Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 185: 634–641.
49. Tu I, Moeyu G, Imai T, Ishida H, Tetsutani K, et al. (2009) Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur J Immunol 39: 3383–3394.
50. Groettrup M, Kirk CJ, Basler M (2010) Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10: 73–78.